Usama Gergis is an Oncology physician affiliated with Thomas Jefferson University. OpenAlex indexes 265 publications with 3,851 citations (h-index 32); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 S Cedar Crest Blvd Ste 401
Allentown, PA 181036218
Telephone
610-402-7880Provider last certified this registry record 28 Oct 2024.
Clinical trials
- Two Step Haplo With Radiation Conditioning
Sponsor: Thomas Jefferson University
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year2025107 payments$105,851openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202529 payments$34,085openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year202520 payments$30,423openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
48.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.9%Valacyclovir100%Part D<11 patientsAzole Antifungal15.8%Noxafil100%Part D<11 patientsMetabolism & gastrointestinal
34.2%Proton pump inhibitor34.2%Pantoprazole Sodium100%Part D<11 patientsCardiovascular
17.1%Calcium channel blocker17.1%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”